Research Focus
研究方向
Developing anti-CD24 monoclonal antibodies and studying CD24 as an immune checkpoint. Our work demonstrates CD24 knockout enhances macrophage- and CD8+ T cell-mediated anti-tumor immune responses.
開發抗 CD24 單株抗體，並研究 CD24 作為免疫檢查點的功能。我們的研究顯示 CD24 基因剔除可增強巨噬細胞及 CD8+ T 細胞介導的抗腫瘤免疫反應。
Engineering next-generation therapeutic antibodies with improved efficacy and safety profiles for cancer treatment, with a focus on rare cancers and triple-negative breast cancer.
開發具有更佳療效與安全性的新一代治療性抗體，重點涵蓋罕見癌症及三陰性乳癌的治療。
Designing dual-antibody-aided mesoporous nanoreactors for combined chemodynamic therapy and immune checkpoint blockade immunotherapy in breast cancer.
設計雙抗體輔助介孔奈米反應器，用於乳癌的化學動力療法與免疫檢查點阻斷聯合治療。
Investigating molecular drivers of cancer metastasis, particularly in triple-negative breast cancer, to identify novel therapeutic vulnerabilities and biomarkers.
研究癌症轉移的分子驅動因素，尤其聚焦於三陰性乳癌，以鑑定新型治療靶點與生物標誌物。
Applying bioinformatics and multi-omics data analysis to uncover cancer biology insights, identify therapeutic targets, and support translational research pipelines.
應用生物資訊學與多組學數據分析，揭示癌症生物學規律，鑑定治療靶標，支持轉譯研究流程。
Exploring the scientific basis and therapeutic potential of Chinese herbal compounds in cancer biology, integrating traditional knowledge with modern oncology research.
探索中草藥化合物在癌症生物學中的科學基礎與治療潛力，將傳統醫學知識與現代腫瘤學研究相結合。
